All eyes are on the preliminary data Moderna is preparing to submit to the monitoring board on its vaccine candidate's effectiveness, which works on technology similar to Pfizer's.
The candidate is a so-called messenger RNA vaccine, based on technology similar to that used by one of the fastest-moving vaccine developers, Moderna Inc.
Moderna decided to make the declaration because investors had started noticing that the company has patents that might apply to other Covid vaccines, says its president.
The vaccine, called mRNA-1273, is being developed by Moderna with the US govt's National Institutes of Health. The small study involved 40 adults aged over 56.
The results from Moderna’s early-stage trial, which include data from 20 participants, are important because older adults often don’t respond as well to vaccines as younger adults.
New Delhi: During Operation Sindoor, the United States which had received intelligence suggesting that India had launched BrahMos cruise missiles to strike targets inside...
COMMENTS